Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
August 28, 2017Share
August 14, 2017Share
Innovators will need to quantify value to bring costly drugs to market.
Real world data essential for CAR-T therapy success
August 3, 2017Share
First patients could be treated in 2019.
Scottish firm gets EU funding for ‘off the shelf’ cancer cell therapy
August 1, 2017Share
Kite eyes possible CAR-T launch next year.
Kite files CAR-T therapy in EU, ahead of Novartis rival
July 21, 2017Share
New 3-year data supports Kite ‘cure’ hopes for CAR-T
July 13, 2017Share
Panel unanimously back CTL019
Novartis close to first-ever CAR-T approval after unanimous vote
July 11, 2017Share
Novartis CAR-T safety in FDA spotlight
July 7, 2017Share
UK firm to supply viruses to generate CAR-T therapies
Oxford BioMedica signs $100m CAR-T deal with Novartis